(All fields required)
Please enter a valid email.
Please enter your name.
Children’s has been issued a US patent for the “Optimization and
Individualization of Medication Selection and Dosing,” a technology that
supports personalized dosing of psychiatric and pain medications.
The technology was
invented by Cincinnati Children’s faculty Tracy Glauser, MD; Alexander Vinks, PharmD, PhD, FCP; and John Pestian, PhD, MBA and Richard Wenstrup, MD, now Chief Medical
Officer at Myriad Genetics, Inc.
Children’s has licensed the technology to Assurex Health, which
has developed pharmacogenomic tests for psychiatric, ADHD, and pain medications
commercialized under the GeneSight® brand.
both the selection and dosing of medications will improve patient outcomes by
providing objective, evidence-based information to tailor treatment programs,”
said Tracy Glauser, MD, Associate Director, Cincinnati Children’s Research
Foundation and lead inventor in a Dec. 2, 2013 announcement. “The issuance of
this patent points to the importance of pharmacogenomic-directed prescribing
and its potential to improve patient care in routine clinical practice.”
Learn more about the new patent.
Register today for Pediatric Insights, our monthly e-newsletter for physicians. Receive the latest information on clinical advancements, research updates and news from Cincinnati Children's.
Subscribe Now >>
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2014 Cincinnati Children's Hospital Medical Center